Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17125596 | METHODS OF TREATING CANCER | December 2020 | February 2024 | Allow | 38 | 2 | 0 | No | No |
| 17123736 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | December 2020 | June 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17119175 | METHOD OF TREATING PATIENTS COADMINISTERED A FACTOR Xa INHIBITOR AND VERAPAMIL | December 2020 | March 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17116086 | COMPOSITION AND METHOD OF AN IRON SUPPLEMENT | December 2020 | August 2023 | Abandon | 32 | 1 | 1 | No | No |
| 17058962 | SCORPION VENOM BENZOQUINONE DERIVATIVES AND USES THEREOF | November 2020 | August 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17058238 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | November 2020 | March 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17101334 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION | November 2020 | March 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17101931 | USE OF KETONE ESTERS FOR PREVENTION OF CNS OXYGEN TOXICITY | November 2020 | March 2024 | Abandon | 40 | 2 | 0 | No | No |
| 17102067 | PHARMACEUTICAL COMBINATION AND USES THEREOF | November 2020 | September 2023 | Allow | 34 | 2 | 0 | No | No |
| 17100664 | NASAL FORMULATIONS OF METOCLOPRAMIDE | November 2020 | November 2022 | Allow | 24 | 4 | 1 | Yes | No |
| 17056521 | Compound for Improving L-Arginine Bioavailability | November 2020 | January 2023 | Allow | 26 | 1 | 0 | No | No |
| 17099298 | METHODS OF TREATMENT WITH CYP3A4 SUBSTRATE DRUGS | November 2020 | May 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17089192 | USE OF MAGNETIC RESONANCE SPECTROSCOPY TO CALIBRATE AND SELECT DOSES, FORMULATIONS, AND DEVICES FOR INTRA-NASAL ADMINISTRATION OF N-ACETYLCYSTEINE | November 2020 | April 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17082902 | METHODS OF TREATMENT | October 2020 | March 2023 | Allow | 29 | 1 | 0 | No | No |
| 17075736 | Storage-stable ready-to-use injectable formulations of Trabectedin | October 2020 | May 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17075907 | ORODISPERSIBLE FORMULATION OF VARDENAFIL | October 2020 | December 2023 | Abandon | 38 | 2 | 0 | No | No |
| 17075819 | INSECTICIDAL COMPOSITIONS AND METHODS | October 2020 | June 2023 | Allow | 31 | 1 | 1 | No | No |
| 17047831 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | October 2020 | May 2024 | Allow | 43 | 2 | 1 | No | Yes |
| 17068916 | METHODS FOR DETERMINING A DRUG DOSING REGIMEN | October 2020 | May 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17064969 | TREATMENT OF MUSCULAR DISORDERS WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | October 2020 | August 2024 | Abandon | 46 | 3 | 0 | No | No |
| 17064898 | SYNERGISTIC FORMULATIONS FOR CONTROL AND REPELLENCY OF BITING ARTHROPODS | October 2020 | December 2023 | Abandon | 38 | 2 | 1 | No | No |
| 17045402 | Bambuterol for the Treatment of Alzheimer's Disease | October 2020 | July 2024 | Abandon | 46 | 2 | 0 | No | No |
| 17060013 | COMPOUNDS FOR USE AS INHIBITORS OF ALTERNATIVE OXIDASE OR CYTOCHROME BC1 COMPLEX | September 2020 | September 2022 | Allow | 24 | 0 | 0 | No | No |
| 17032489 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | September 2020 | July 2024 | Abandon | 46 | 1 | 1 | No | No |
| 17041815 | ALKYNE COMPOUND AND ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME | September 2020 | August 2022 | Allow | 23 | 0 | 0 | Yes | No |
| 17027352 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | September 2020 | June 2023 | Allow | 33 | 1 | 0 | No | No |
| 17024752 | CANNABINOID RECEPTOR MODULATORS | September 2020 | March 2023 | Allow | 30 | 1 | 0 | No | No |
| 17025853 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation | September 2020 | February 2023 | Abandon | 29 | 0 | 1 | No | No |
| 16979001 | ORGANIC AMINE ESTER DERIVATIVE DRUG OF 2-(alpha-HYDROXYPENTYL)BENZOIC ACID | September 2020 | June 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 16969261 | NOVEL CRYSTALLINE FORMS OF TAMIBAROTENE FOR TREATMENT OF CANCER | August 2020 | November 2023 | Abandon | 40 | 0 | 1 | No | No |
| 16989689 | COMPOUNDS FOR THERAPEUTIC USE | August 2020 | February 2023 | Abandon | 30 | 1 | 0 | No | No |
| 16938628 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING GLAUCOMA | July 2020 | January 2022 | Allow | 18 | 2 | 1 | Yes | No |
| 16932508 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | July 2020 | June 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16930487 | ANTI-ANDROGENS FOR THE TREATMENT OF PROSTRATE CANCER | July 2020 | June 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16920512 | COMPOSITIONS CONTAINING FORMALDEHYDE AND ORGANIC ACID FOR PREVENTION OF AFRICAN SWINE FEVER | July 2020 | August 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16874251 | TREATMENT OF POLYCYSTIC DISEASES WITH AN HDAC6 INHIBITOR | May 2020 | January 2023 | Allow | 32 | 1 | 1 | No | No |
| 16870653 | SOLID STATE FORMS OF FUSED HETEROAROMATIC PYRROLIDINONES | May 2020 | February 2022 | Allow | 21 | 1 | 1 | No | No |
| 16759051 | ORAL HYPOGLYCEMIC AGENTS AS FOOD ADDITIVES AND SUPPLEMENTS | April 2020 | October 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16853361 | TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT | April 2020 | June 2022 | Allow | 26 | 1 | 1 | No | No |
| 16756112 | AQUEOUS COMPOSITIONS COMPRISING BILASTINE AND MOMETASONE | April 2020 | February 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 16842686 | METHODS OF SKIN WHITENING BY USE OF CANOLA EXTRACTS | April 2020 | September 2023 | Allow | 42 | 3 | 1 | Yes | No |
| 16839369 | COMBINATION OF DIET AND DRUG THERAPY FOR TREATING CANCER | April 2020 | November 2023 | Abandon | 43 | 2 | 1 | No | No |
| 16839972 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | April 2020 | December 2021 | Abandon | 21 | 1 | 1 | No | No |
| 16651238 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTITUMOR EFFECT BY IMMUNE CHECKPOINT INHIBITOR | March 2020 | November 2021 | Allow | 19 | 2 | 1 | No | No |
| 16829484 | Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same | March 2020 | November 2022 | Abandon | 32 | 2 | 1 | No | No |
| 16804802 | METHODS FOR TREATING ALZHEIMER'S DISEASE AND RELATED DISORDERS | February 2020 | January 2024 | Abandon | 46 | 3 | 1 | No | No |
| 16873190 | Method of reducing anxiety in non-human mammals by increasing brain serotonin levels | February 2020 | March 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16633540 | CYTISINE SALTS | January 2020 | May 2022 | Allow | 27 | 0 | 1 | Yes | No |
| 16631761 | COMPOSITION COMPRISING ETHYL VANILLIN AS EFFECTIVE INGREDIENT FOR EXHIBITING EFFECT OF MUSCLE STRENGTHENING, MUSCLE ENHANCEMENT, MUSCLE DIFFERENTIATION, MUSCLE REGENERATION, OR SARCOPENIA SUPPRESSION | January 2020 | October 2022 | Allow | 33 | 1 | 1 | No | No |
| 16720574 | CO-CRYSTALS OF TRAMADOL AND COXIBS | December 2019 | June 2022 | Allow | 30 | 2 | 0 | No | No |
| 16712815 | NOVEL THYROMIMETICS | December 2019 | June 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16621942 | ORAL DRUG DELIVERY COMPOSITION CONTAINING OXALIPLATIN AND METHOD FOR PREPARING SAME | December 2019 | July 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16702819 | METHOD OF IMPROVING MUSCLE AND CONNECTIVE TISSUE WITH SHILAJIT | December 2019 | April 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16701705 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | December 2019 | May 2023 | Abandon | 42 | 2 | 1 | No | No |
| 16684439 | DIAGNOSIS OF DIABETES BY DETECTING AGGREGATED AMYLIN IN ERYTHROCYTES | November 2019 | May 2024 | Allow | 54 | 5 | 1 | Yes | No |
| 16667159 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | October 2019 | January 2021 | Allow | 14 | 1 | 1 | Yes | No |
| 16665774 | Method and Composition for Increasing the Bioavailability of Carnitine | October 2019 | February 2023 | Abandon | 39 | 2 | 1 | Yes | No |
| 16666323 | REDUCED ADAPTIVE MICROBIAL RESISTANCE TREATMENT FOR FLESH EATING DISEASE (necrotizing fasciitis) | October 2019 | September 2023 | Allow | 47 | 2 | 1 | No | No |
| 16606534 | COMBINATIONS INCLUDING BETA-ADRENORECEPTOR AGONISTS FOR TREATMENT OF PARKINSON`S DISEASE AND MOVEMENT DISORDERS | October 2019 | November 2023 | Abandon | 49 | 3 | 1 | Yes | Yes |
| 16580697 | CANNABINOID RECEPTOR MODULATORS | September 2019 | September 2021 | Allow | 24 | 3 | 0 | No | No |
| 16573371 | COMBINATION THERAPY FOR TREATING CANCER | September 2019 | December 2021 | Abandon | 27 | 1 | 1 | No | No |
| 16569109 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | September 2019 | March 2022 | Abandon | 30 | 3 | 1 | Yes | No |
| 16561990 | COMPOSITIONS AND METHODS USING A POLYPHENOL FOR MUSCULOSKELETAL HEALTH | September 2019 | February 2022 | Allow | 29 | 2 | 1 | Yes | No |
| 16560806 | DRUG COMPOSITIONS | September 2019 | January 2021 | Allow | 17 | 1 | 1 | No | No |
| 16559006 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | September 2019 | June 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16530380 | METHODS FOR TREATING PANCREATIC CANCER | August 2019 | October 2023 | Allow | 50 | 2 | 1 | Yes | No |
| 16523493 | FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | July 2019 | March 2021 | Abandon | 19 | 1 | 1 | No | No |
| 16479382 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | July 2019 | February 2021 | Allow | 19 | 1 | 1 | Yes | No |
| 16514722 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | July 2019 | October 2021 | Abandon | 27 | 1 | 1 | No | No |
| 16450163 | METHODS OF INHIBITING MICROBIAL INFECTIONS USING ZINC-CONTAINING COMPOSITIONS | June 2019 | April 2024 | Allow | 58 | 7 | 1 | Yes | Yes |
| 16440304 | STABLE PHARMACEUTICAL FORMULATIONS OF METHYLNALTREXONE | June 2019 | May 2022 | Abandon | 35 | 3 | 1 | No | No |
| 16439570 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | June 2019 | June 2022 | Allow | 36 | 2 | 1 | Yes | No |
| 16408931 | METHODS OF TREATMENT | May 2019 | October 2020 | Allow | 17 | 0 | 1 | Yes | No |
| 16405503 | METHODS OF TREATING OPTIC DISORDERS | May 2019 | December 2021 | Allow | 32 | 3 | 1 | No | No |
| 16402231 | Novel Route of Nasal Administration of Aripiprazole for Treatment of Eating Disorders | May 2019 | April 2022 | Abandon | 35 | 1 | 1 | No | No |
| 16402068 | TREATMENT OF BRAIN CANCER | May 2019 | September 2021 | Allow | 28 | 3 | 1 | Yes | No |
| 16398026 | PHARMACEUTICAL COMPOSITION AND METHOD FOR REGENERATING MYOFIBERS IN THE TREATMENT OF MUSCLE INJURIES | April 2019 | December 2020 | Abandon | 20 | 1 | 1 | No | No |
| 16396071 | NEOSAXITOXIN COMBINATION FORMULATIONS FOR PROLONGED LOCAL ANESTHESIA | April 2019 | September 2020 | Allow | 17 | 2 | 1 | Yes | No |
| 16344492 | METHODS OF TREATMENT FOR MYELOID LEUKEMIA | April 2019 | November 2020 | Abandon | 18 | 1 | 1 | No | No |
| 16373428 | THERAPEUTIC INHIBITORY COMPOUNDS | April 2019 | February 2021 | Allow | 22 | 1 | 1 | No | No |
| 16336424 | Methods for Treating Pruritis | March 2019 | September 2022 | Abandon | 42 | 3 | 1 | No | No |
| 16351262 | METHOD FOR PREVENTING OR TREATING VIRAL INFECTION AND TUMOR | March 2019 | May 2020 | Allow | 14 | 1 | 1 | Yes | No |
| 16351198 | METHODS OF TREATMENT | March 2019 | May 2020 | Abandon | 14 | 1 | 0 | No | No |
| 16289857 | GEL COMPOSITION | March 2019 | May 2022 | Allow | 39 | 3 | 1 | No | No |
| 16275437 | CO-CRYSTALS OF TRAMADOL AND COXIBS | February 2019 | September 2019 | Allow | 7 | 1 | 0 | No | No |
| 16259685 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | January 2019 | February 2022 | Allow | 37 | 3 | 1 | No | Yes |
| 16257641 | Use of N-acetylcysteine Amide in the Treatment Of Disease and Injury | January 2019 | October 2021 | Abandon | 33 | 2 | 1 | No | No |
| 16257287 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | January 2019 | January 2020 | Abandon | 12 | 0 | 1 | No | No |
| 15763023 | ANTIBACTERIAL AND ANTIFUNGAL COMPOUNDS | January 2019 | February 2023 | Allow | 59 | 4 | 1 | Yes | Yes |
| 16242266 | METHODS OF SKIN WHITENENING BY USE OF CANOLA EXTRACTS | January 2019 | May 2020 | Abandon | 16 | 0 | 1 | No | No |
| 16236942 | TRANSDERMAL DELIVERY OF DICLOFENAC, CARBAMAZEPINE AND BENZYDAMINE | December 2018 | March 2022 | Abandon | 38 | 2 | 1 | No | No |
| 16225910 | METHOD OF TREATING PATIENTS COADMINISTERED A FACTOR Xa INHIBITOR AND VERAPAMIL | December 2018 | June 2020 | Abandon | 18 | 1 | 0 | Yes | No |
| 16306226 | SOLID ORAL DOSAGE FORMS OF 2R,6R-HYDROXYNORKETAMINE OR DERIVATIVES THEREOF | November 2018 | July 2023 | Abandon | 55 | 4 | 1 | No | No |
| 16201481 | METHOD OF TREATING PATIENTS COADMINISTERED A FACTOR Xa INHIBITOR AND VERAPAMIL | November 2018 | October 2020 | Abandon | 23 | 2 | 0 | Yes | No |
| 16304955 | SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING | November 2018 | September 2022 | Allow | 45 | 1 | 1 | No | No |
| 16302574 | APPLICATIONS OF NOVEL THIAZOLE DERIVATIVE IN TREATING INFLAMMATORY BOWEL DISEASES | November 2018 | August 2022 | Allow | 45 | 4 | 1 | No | No |
| 16302084 | COMBINATION THERAPIES USING INDAZOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | November 2018 | July 2020 | Abandon | 20 | 1 | 1 | No | No |
| 16301936 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | November 2018 | September 2020 | Allow | 22 | 1 | 1 | No | No |
| 16191351 | METHODS OF TREATMENT WITH CYP3A4 SUBSTRATE DRUGS | November 2018 | September 2020 | Allow | 22 | 2 | 1 | Yes | No |
| 16300552 | METHODS AND COMPOSITIONS FOR TREATING ADVANCED STAGE NON-SMALL CELL LUNG CANCER | November 2018 | June 2023 | Allow | 55 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, WILLIAM Y.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 9.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEE, WILLIAM Y works in Art Unit 1629 and has examined 604 patent applications in our dataset. With an allowance rate of 42.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner LEE, WILLIAM Y's allowance rate of 42.7% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LEE, WILLIAM Y receive 2.26 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LEE, WILLIAM Y is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +37.6% benefit to allowance rate for applications examined by LEE, WILLIAM Y. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.2% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 29.7% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 87.0% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 60.5% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.4% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.